Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.12.2014 | review | Ausgabe 4/2014

memo - Magazine of European Medical Oncology 4/2014

Is there a role for angiogenesis inhibition in prostate cancer?

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 4/2014
Autoren:
MD, PhD Isabel Heidegger, MD, PhD Andreas Pircher, MD Assoc. Prof. Jasmin Bektic

Abstract

Prostate cancer is the most common male cancer and one of the most common causes of cancer death among men in European countries. In the last years, a large number of new drugs for treatment of castration-resistant prostate cancer (CRPC) have been approved, others are still in an advanced stage of clinical testing. In this review, we provide an overview on new substances which act via modulation or inhibition of angiogenesis. Results and limitations from clinical studies as well as future needs for improvement of those agents in CRPC are critically discussed.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2014

memo - Magazine of European Medical Oncology 4/2014 Zur Ausgabe